Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678725 | 0.90 | FOLH1 (0.46) | FOLH1ATMKMT2AMEN1ABCB1 | |
| SCHEMBL29679326 | 0.90 | FOLH1 (0.49) | FOLH1ATMKMT2AMEN1ABCB1 | |
| SCHEMBL29679454 | 0.89 | FOLH1 (0.45) | FOLH1ATMKMT2APLGPRSS1 | |
| SCHEMBL29679205 | 0.89 | FOLH1 (0.45) | FOLH1ATMKMT2APLGPRSS1 | |
| SCHEMBL29679264 | 0.89 | FOLH1 (0.45) | FOLH1 | |
| SCHEMBL29679332 | 0.87 | FOLH1 (0.50) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29679150 | 0.87 | FOLH1 (0.50) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29679148 | 0.86 | FOLH1 (0.48) | FOLH1ATMKMT2AMEN1ABCB1 | |
| SCHEMBL29679232 | 0.83 | FOLH1 (0.45) | FOLH1ATMKMT2AMEN1PLG | |
| SCHEMBL29679398 | 0.82 | FOLH1 (0.60) | FOLH1ATMKMT2AMEN1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, AR, SHBG | FOLH1 43/4885ATM 2227/4885KMT2A 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.